You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
News items for the week of Jan. 11, 2021.
Buoyed by a string of positive news, the San Diego firm's stock was up 22 percent in Friday afternoon trading and 80 percent from last week.
Ancestry will focus more on family history and genetic genealogy, and called the move a "strategic but difficult decision."
The sequencing company reported preliminary fourth quarter revenues of $27 million and said it currently has $318 million in cash and investments.
The contract was awarded under DARPA's Detect It with Gene Editing Technologies program, which aims to create a device to detect at least 10 pathogens.
The test has been authorized for use with individual respiratory specimens, as well as with pooled specimens containing up to five samples.
Exact Sciences discussed new Cologuard data; Danaher reviewed Cepheid's 2020 performance; and NanoString talked about forthcoming spatial biology products.
Invitae is working with Bristol Myers Squibb, Janssen, Novartis, and Genentech to advance an NGS panel to gauge the efficacy of AML treatments in trials.
The company said it expects core molecular testing revenue between $115 million and $125 million and SARS-CoV-2 revenue between $15 million and $20 million.
The firm plans to begin its OTC efforts with a COVID antigen test but also sees potential in migrating other infectious disease tests.
Using its xT sequencing platform, Tempus will create a companion test to identify patients eligible for treatment with A2's cell-based LOH-targeted therapy.
The researchers found likely deleterious de novo tandem repeat mutations that were more common among individuals with autism spectrum disorder.
The funding will be used to validate the Simplexa COVID-19 Direct kit and Simplexa COVID-19 & Flu A/B Direct kit and to submit them to the FDA for 510(k) clearance.
ZeptoMetrix develops and manufactures quality control standards and verification panels used in infectious disease molecular diagnostic testing.
Qiagen's CEO discussed the company's focus on specific growth drivers, while Invitae's CEO talked about pandemic-related challenges in its genetic testing business.
The drugmaker is supporting access to NGS testing in these countries to identify lung and pancreatic cancer patients with NRG1 fusions who can join its study.
The company also projected full year 2020 revenue of between $84 million and 86 million and said that its instrument install base grew 34 percent over the year.
Laboratories that purchase PGDx Elio genomic profiling tests will receive access to Qiagen's QCI Interpret One for rapid, evidence-based variant interpretation.
Despite the Q4 revenue increase, sales for FY2020 dropped 13 percent year over year to $5.2 million.
The partners will use PacBio's HiFi sequencing to develop assays for carrier screening, evaluating immune system responses, and diagnosing heritable diseases.
Last year, the company processed more than 1 million tests, most of them for its reproductive health business, but interest in Prospera and Signatera is growing.
The researchers developed an approach to mitigate the effects of misreporting or longitudinal changes in drinking behavior.
The company said it will use the financing to further develop its Transistor molecular detection platform and significantly expand mass manufacturing.
Reuters reports that Germany is seeking to sequence 5 percent of patient samples that test positive for SARS-CoV-2.
23andMe and Medscape say primary care physicians are increasingly more comfortable with discussing direct-to-consumer genetic testing results.
The publisher of the Science family of journals will allow some authors to place peer-reviewed versions of their papers into publicly accessible repositories.
In Science this week: analysis of genome-wide association studies of chronic kidney disease, and more.